345 related articles for article (PubMed ID: 19758183)
1. The role of iNKT cells in the immunopathology of systemic lupus erythematosus.
Gabriel L; Morley BJ; Rogers NJ
Ann N Y Acad Sci; 2009 Sep; 1173():435-41. PubMed ID: 19758183
[TBL] [Abstract][Full Text] [Related]
2. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of regulation of autoimmunity by iNKT cells.
Novak J; Lehuen A
Cytokine; 2011 Mar; 53(3):263-70. PubMed ID: 21185200
[TBL] [Abstract][Full Text] [Related]
4. The development of airway hyperreactivity in T-bet-deficient mice requires CD1d-restricted NKT cells.
Kim HY; Pichavant M; Matangkasombut P; Koh YI; Savage PB; DeKruyff RH; Umetsu DT
J Immunol; 2009 Mar; 182(5):3252-61. PubMed ID: 19234223
[TBL] [Abstract][Full Text] [Related]
5. Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus.
Godó M; Sessler T; Hamar P
Curr Med Chem; 2008; 15(18):1778-87. PubMed ID: 18691038
[TBL] [Abstract][Full Text] [Related]
6. Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production.
Shen L; Zhang H; Caimol M; Benike CJ; Chakravarty EF; Strober S; Engleman EG
Eur J Immunol; 2015 Feb; 45(2):612-23. PubMed ID: 25352488
[TBL] [Abstract][Full Text] [Related]
7. Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15.
Hsu CY; Chueh YS; Kuo ML; Lee PT; Hsiao HS; Huang JL; Lin SJ
PLoS One; 2021; 16(12):e0261727. PubMed ID: 34936686
[TBL] [Abstract][Full Text] [Related]
8. The in vivo response of invariant natural killer T cells to glycolipid antigens.
Parekh VV; Lalani S; Van Kaer L
Int Rev Immunol; 2007; 26(1-2):31-48. PubMed ID: 17454263
[TBL] [Abstract][Full Text] [Related]
9. TLR9-induced miR-155 and Ets-1 decrease expression of CD1d on B cells in SLE.
Liu F; Fan H; Ren D; Dong G; Hu E; Ji J; Hou Y
Eur J Immunol; 2015 Jul; 45(7):1934-45. PubMed ID: 25929465
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases.
Miyake S; Yamamura T
Int Rev Immunol; 2007; 26(1-2):73-94. PubMed ID: 17454265
[TBL] [Abstract][Full Text] [Related]
11. CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences.
Florence WC; Bhat RK; Joyce S
Expert Rev Mol Med; 2008 Jul; 10():e20. PubMed ID: 18601810
[TBL] [Abstract][Full Text] [Related]
12. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis.
Bharhani MS; Chiu B; Na KS; Inman RD
Int Immunol; 2009 Jul; 21(7):859-70. PubMed ID: 19477915
[TBL] [Abstract][Full Text] [Related]
13. Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis.
Sireci G; Russo D; Dieli F; Porcelli SA; Taniguchi M; La Manna MP; Di Liberto D; Scarpa F; Salerno A
Eur J Immunol; 2007 Feb; 37(2):425-33. PubMed ID: 17273990
[TBL] [Abstract][Full Text] [Related]
14. Modulatory function of invariant natural killer T cells in systemic lupus erythematosus.
Chuang YP; Wang CH; Wang NC; Chang DM; Sytwu HK
Clin Dev Immunol; 2012; 2012():478429. PubMed ID: 22761630
[TBL] [Abstract][Full Text] [Related]
15. Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells.
Bosma A; Abdel-Gadir A; Isenberg DA; Jury EC; Mauri C
Immunity; 2012 Mar; 36(3):477-90. PubMed ID: 22406267
[TBL] [Abstract][Full Text] [Related]
16. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice.
Forestier C; Molano A; Im JS; Dutronc Y; Diamond B; Davidson A; Illarionov PA; Besra GS; Porcelli SA
J Immunol; 2005 Jul; 175(2):763-70. PubMed ID: 16002672
[TBL] [Abstract][Full Text] [Related]
17. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity.
Lynch L; O'Shea D; Winter DC; Geoghegan J; Doherty DG; O'Farrelly C
Eur J Immunol; 2009 Jul; 39(7):1893-901. PubMed ID: 19585513
[TBL] [Abstract][Full Text] [Related]
18. Invariant natural killer T cells and immunotherapy of cancer.
Molling JW; Moreno M; van der Vliet HJ; van den Eertwegh AJ; Scheper RJ; von Blomberg BM; Bontkes HJ
Clin Immunol; 2008 Nov; 129(2):182-94. PubMed ID: 18783990
[TBL] [Abstract][Full Text] [Related]
19. Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus.
Hofmann SC; Bosma A; Bruckner-Tuderman L; Vukmanovic-Stejic M; Jury EC; Isenberg DA; Mauri C
J Dermatol Sci; 2013 Jul; 71(1):22-8. PubMed ID: 23664188
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer.
Motohashi S; Okamoto Y; Yoshino I; Nakayama T
Clin Immunol; 2011 Aug; 140(2):167-76. PubMed ID: 21349771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
